Drug intelligence / Profile preview

S236220

Development stage: Preclinical
Lead developer: Servier

Overview

S236220 is an investigational drug candidate currently in preclinical development for the treatment of hematological malignancies. Developed through the partnership between Servier and its subsidiary Symphogen, the specific biological target and therapeutic modality (such as small molecule or monoclonal antibody) have not yet been publicly disclosed. It represents an early-stage asset in Servier's oncology portfolio aimed at addressing various forms of blood-borne cancers.

Beyond the preview

Go deeper on S236220.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S236220.

Explore the full profile